蛋白质精氨酸甲基转移酶5
药效团
化学
精氨酸
小分子
酶
生物化学
细胞周期检查点
甲基转移酶
甲基化
细胞周期
氨基酸
细胞凋亡
基因
作者
Kongkai Zhu,Jiali Song,Hongrui Tao,Zhiqiang Cheng,Cheng‐Shi Jiang,Hua Zhang
标识
DOI:10.1016/j.bmcl.2018.10.026
摘要
Protein arginine methyltransferase 5 (PRMT5) is an epigenetics related enzyme that has been validated as a promising therapeutic target for human cancer. Up to now, two small molecule PRMT5 inhibitors has been put into phase I clinical trial. In the present study, a series of candidate molecules were designed by combining key pharmacophores of formerly reported PRMT5 inhibitors. The in vitro PRMT5 inhibitory testing of compound 4b14 revealed an IC50 of 2.71 μM, exhibiting high selectivity over PRMT1 and PRMT4 (>70-fold selective). As expected, 4b14 exhibited potent anti-proliferative activity against a panel of leukemia and lymphoma cells, including MV4-11, Pfeiffer, SU-DHL-4 and KARPAS-422. Besides, 4b14 showed significant cell cycle arrest and apoptosis-inducing effects, as well as reduced the cellular symmetric arginine dimethylation level of SmD3 protein. Finally, affinity profiling analysis indicated that hydrophobic interactions, π-π stacking and cation-π actions made the major contributions to the overall binding affinity. This scaffold provides a new chemical template for further development of better lead compounds targeting PRMT5.
科研通智能强力驱动
Strongly Powered by AbleSci AI